The Knowledge Hub

What is the Knowledge Hub?

Explore the VoICE Knowledge Hub—a searchable database featuring the latest peer-reviewed research on immunization benefits, especially in low- and middle-income countries. Browse the Knowledge Hub using a variety of different filters to find vaccine evidence based on country, region, topic, or disease. Click on a tag to find more evidence on a specific area, such as the return on investment of vaccines or impacts of infectious disease outbreaks.


Diseases & Vaccines


WHO Regions


Immunization Terms

Maternal pertussis vaccination in Argentina reduced pertussis incidence in infants under 2 months by half

In Argentina, more than 50% of deaths due to pertussis occurred in infants younger than 2 months of age — too young to be vaccinated in the country. The impact of maternal pertussis vaccination in protecting their infants against the disease reduced the incidence of pertussis in infants less than 2 months old by half, when comparing states with high and low maternal vaccination rates.

Vizzotti C, Juarez MV, Bergel E et al.. 2016. Impact of a maternal immunization program against pertussis in a developing country. Vaccine. 34(50).

Vaccinating pregnant women with Tdap vaccine is 81% effective in preventing pertussis in infants

Vaccinating women during their second or third trimester of pregnancy with the Tdap vaccine was 81% effective in preventing pertussis in their infants in the first two months of life, according to a case-control study in Argentina.

This is one of the first studies to measure the effectiveness of maternal pertussis vaccination in a middle-income country and its findings support Argentina’s decision to introduce the vaccine.

Romanin V, Acosta AM, Del Valle Juarez M et al.. 2020. Maternal vaccination in Argentina: tetanus, diphtheria, and acellular pertussis vaccine effectiveness during pregnancy in preventing pertussis in infants <2 months of age. Clinical Infectious Diseases. 70(3).

Childhood vaccination against Hepatitis A is cost-effective

In Argentina, universal vaccination for Hepatitis A in children, at 95% vaccine coverage, can prevent over 350,000 hepatitis A infections per year and 428 deaths. Benefits persist at coverage rates as low as 70% with over 290,000 prevented infections. At 95% coverage rates, this program would save almost $24,000 annually.

Lopez, E., Debbag, R., Coudeville, L., et al. 2007. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. Journal of Gastroenterology. 42(2).

In Argentina, PCV immunization is a highly cost effective strategy

PCV7 use in Argentina resulted in an estimated cost of US$5,599 per life year gained. The purchase of the 4 doses of vaccine for the entire cohort at a cost of US$26.5 per dose would required an investment of US$73,823,806.00. This investment would significantly reduce the number of deaths brought about by cases of meningitis, bacteremia, pneumonia, otitis media and meningitis sequelae. The resultant decrease in morbidity and mortality coupled with herd immunity offered by immunization would contribute substantially to national productivity making PCV immunization a highly cost effective strategy.

Giglio, N.D., Cane, A.D., Micone, P., et al. 2010. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine. 28(11).